Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127229471 | 12722947 | 1 | I | 20160829 | 20160908 | 20160908 | EXP | FR-ROCHE-1822714 | ROCHE | PHILIPPE L, HELIAS P, PUYRAVEAU M, BOULAHDOUR H, DECONINCK E, AND DAGUINDAU E. LONG-TERM FOLLOW-UP OF 90 Y-IBRITUMOMAB-TIUXETAN (90 YIT) IN THE CONDITIONING OF AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION FOR INDOLENT AND MANTLE CELL LYMPHOMAS IN A SINGLE FRENCH CENTER. BONE MARROW TRANSPLANTATION 2016 AUG 01;51 (8):1140-1142. | 0.00 | Y | 0.00000 | 20160908 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127229471 | 12722947 | 1 | PS | Rituximab | RITUXIMAB | 1 | Unknown | U | 103705 | ||||||||||
| 127229471 | 12722947 | 2 | SS | Rituximab | RITUXIMAB | 1 | U | 103705 | |||||||||||
| 127229471 | 12722947 | 3 | SS | Rituximab | RITUXIMAB | 1 | U | 103705 | |||||||||||
| 127229471 | 12722947 | 4 | SS | Rituximab | RITUXIMAB | 1 | U | 103705 | |||||||||||
| 127229471 | 12722947 | 5 | SS | CARMUSTINE | CARMUSTINE | 1 | Unknown | U | 0 | ||||||||||
| 127229471 | 12722947 | 6 | SS | CARMUSTINE | CARMUSTINE | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 7 | SS | CARMUSTINE | CARMUSTINE | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 8 | SS | CARMUSTINE | CARMUSTINE | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 9 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Unknown | 200 OR 400 MG/M2. | U | 0 | |||||||||
| 127229471 | 12722947 | 10 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 11 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 12 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 13 | SS | CYTARABINE. | CYTARABINE | 1 | Unknown | 200 OR 400 MG/M2. | U | 0 | |||||||||
| 127229471 | 12722947 | 14 | SS | CYTARABINE. | CYTARABINE | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 15 | SS | CYTARABINE. | CYTARABINE | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 16 | SS | CYTARABINE. | CYTARABINE | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 17 | SS | MELPHALAN | MELPHALAN | 1 | Unknown | U | 0 | ||||||||||
| 127229471 | 12722947 | 18 | SS | MELPHALAN | MELPHALAN | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 19 | SS | MELPHALAN | MELPHALAN | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 20 | SS | MELPHALAN | MELPHALAN | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 21 | SS | IBRITUMOMAB TIUXETAN/YTTRIUM-90 | IBRITUMOMAB TIUXETAN | 1 | Unknown | U | 0 | ||||||||||
| 127229471 | 12722947 | 22 | SS | IBRITUMOMAB TIUXETAN/YTTRIUM-90 | IBRITUMOMAB TIUXETAN | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 23 | SS | IBRITUMOMAB TIUXETAN/YTTRIUM-90 | IBRITUMOMAB TIUXETAN | 1 | U | 0 | |||||||||||
| 127229471 | 12722947 | 24 | SS | IBRITUMOMAB TIUXETAN/YTTRIUM-90 | IBRITUMOMAB TIUXETAN | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127229471 | 12722947 | 1 | Non-Hodgkin's lymphoma |
| 127229471 | 12722947 | 2 | B-cell lymphoma |
| 127229471 | 12722947 | 3 | Mantle cell lymphoma |
| 127229471 | 12722947 | 4 | Marginal zone lymphoma |
| 127229471 | 12722947 | 5 | Non-Hodgkin's lymphoma |
| 127229471 | 12722947 | 6 | B-cell lymphoma |
| 127229471 | 12722947 | 7 | Mantle cell lymphoma |
| 127229471 | 12722947 | 8 | Marginal zone lymphoma |
| 127229471 | 12722947 | 9 | Non-Hodgkin's lymphoma |
| 127229471 | 12722947 | 10 | B-cell lymphoma |
| 127229471 | 12722947 | 11 | Mantle cell lymphoma |
| 127229471 | 12722947 | 12 | Marginal zone lymphoma |
| 127229471 | 12722947 | 13 | Non-Hodgkin's lymphoma |
| 127229471 | 12722947 | 14 | B-cell lymphoma |
| 127229471 | 12722947 | 15 | Mantle cell lymphoma |
| 127229471 | 12722947 | 16 | Marginal zone lymphoma |
| 127229471 | 12722947 | 17 | B-cell lymphoma |
| 127229471 | 12722947 | 18 | Mantle cell lymphoma |
| 127229471 | 12722947 | 19 | Marginal zone lymphoma |
| 127229471 | 12722947 | 20 | Non-Hodgkin's lymphoma |
| 127229471 | 12722947 | 21 | B-cell lymphoma |
| 127229471 | 12722947 | 22 | Mantle cell lymphoma |
| 127229471 | 12722947 | 23 | Marginal zone lymphoma |
| 127229471 | 12722947 | 24 | Non-Hodgkin's lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127229471 | 12722947 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127229471 | 12722947 | Bacterial colitis | |
| 127229471 | 12722947 | Bronchopulmonary aspergillosis | |
| 127229471 | 12722947 | Cystitis bacterial | |
| 127229471 | 12722947 | Gastrointestinal toxicity | |
| 127229471 | 12722947 | Infectious colitis | |
| 127229471 | 12722947 | Mucosal inflammation | |
| 127229471 | 12722947 | Staphylococcal bacteraemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |